Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Development of a novel antisense therapy for facioscapulohumeral muscular dystrophy

FY 2016-17

Summary
Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder characterized by the progressive wasting of muscles in the face, shoulders, and lower limbs. It is the third most common form of muscular dystrophy. FSHD is caused by abnormal production in muscle of a protein called DUX4, which is not found in healthy individuals. This harmful protein induces muscle damage, as seen in FSHD patients. FSHD has a variable age of onset, with patients facing a lifetime of disability when it manifests. There is also a severe juvenile form of FSHD that leads to early wheelchair-dependence in childhood. FSHD patients are thus in need of a treatment, but none exists at present.My project aims to develop a novel therapy for FSHD using small DNA-like molecules called antisense oligonucleotide gapmers. Gapmers are able to bind target gene products, e.g. those giving rise to the DUX4 protein, and mark them for degradation by the cell. I propose to use these gapmers to specifically reduce DUX4 protein levels in FSHD patient muscles. I will be testing the efficacy and safety of a set of these gapmers in FSHD patient-derived muscle cells. Following cell-based screening, further testing of selected gapmers will be done in an FSHD mouse model. At the end of this study, I will have identified a promising clinical trial drug candidate for FSHD therapy. This should help provide FSHD patients with a viable treatment option in the long run, giving them the prospect of an improved quality of life.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
367213
Name
Lim Kenji Rowel Q
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a novel antisense therapy for facioscapulohumeral muscular dystrophy
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antisense Therapy; Drug Development; Facioscapulohumeral Muscular Dystrophy; Gene Expression Inhibition; Human Cell Line; In Vitro Drug Screening; Locked Nucleic Acid Gapmers; Medical Genetics; Muscle; Translational Research
Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder characterized by the progressive wasting of muscles in the face, shoulders, and lower limbs. It is the third most common form of muscular dystrophy. FSHD is caused by abnormal production in muscle of a protein called DUX4, which is not found in healthy individuals. This harmful protein induces muscle damage, as seen in FSHD patients. FSHD has a variable age of onset, with patients facing a lifetime of disability when it manifests. There is also a severe juvenile form of FSHD that leads to early wheelchair-dependence in childhood. FSHD patients are thus in need of a treatment, but none exists at present.My project aims to develop a novel therapy for FSHD using small DNA-like molecules called antisense oligonucleotide gapmers. Gapmers are able to bind target gene products, e.g. those giving rise to the DUX4 protein, and mark them for degradation by the cell. I propose to use these gapmers to specifically reduce DUX4 protein levels in FSHD patient muscles. I will be testing the efficacy and safety of a set of these gapmers in FSHD patient-derived muscle cells. Following cell-based screening, further testing of selected gapmers will be done in an FSHD mouse model. At the end of this study, I will have identified a promising clinical trial drug candidate for FSHD therapy. This should help provide FSHD patients with a viable treatment option in the long run, giving them the prospect of an improved quality of life.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lim, Kenji Rowel Q
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~